Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
medrxiv; 2024.
Preprint in English | medRxiv | ID: ppzbmed-10.1101.2024.02.13.24302237

ABSTRACT

A globally implemented unified classification for human respiratory syncytial virus (HRSV) below the subgroup level remains elusive. Here, we formulate the global consensus of HRSV classification based on the challenges and limitations of our previous proposals and the future of genomic surveillance. From a high-quality dataset of 1,480 HRSV-A and 1,385 HRSV-B genomes submitted to NCBI and GISAID up to March 2023, we categorized HRSV-A/B sequences into lineages based on phylogenetic clades and amino acid markers. We defined 24 lineages within HRSV-A and 16 within HRSV-B, providing guidelines for prospective lineages definition. Our classification demonstrated robustness in its applicability to both complete and partial genomes. In addition, it allowed the observation of notable lineage replacements and the identification of lineages exclusively detected since the COVID-19 pandemic. We envision that this unified HRSV classification proposal will strengthen and facilitate HRSV molecular epidemiology on a global scale.


Subject(s)
COVID-19 , Respiratory Syncytial Virus Infections
2.
J Clin Virol ; 149: 105126, 2022 04.
Article in English | MEDLINE | ID: covidwho-1729892

ABSTRACT

INTRODUCTION: The community mitigation measures taken because of the COVID-19 pandemic had side effects on the circulation of the most frequent respiratory viruses during 2020. In the case of respiratory syncytial virus (RSV), an important paediatric pathogen, a decrease in the number of cases and delayed outbreaks was previously described. AIM AND METHODS: The genetic characteristics of the RSV circulating strains in paediatric patients in Buenos Aires, Argentina before and during the COVID-19 pandemic were studied. RSV (+) samples taken from hospitalised patients with respiratory tract infections (2018- 2021) were analysed through G gene sequencing and evolutionary analyses. RESULTS: No RSV hospitalised paediatric patients were registered in Buenos Aires during 2020; however, RSV reemerged in 2021 with a lower number of cases and a delayed outbreak, peaking in July-August. A total of 147 G gene sequences were analysed. RSV-B (N = 85) predominated during 2018 and 2021 whereas in 2019 RSV-A were more prevalent (N = 62). All RSV-A sequences were ON1-like strains, and all RSV-B were BA-like. Phylogenetic analyses showed that the same genetic lineages circulated before and after 2020, but RSVs from 2021 corresponded to new viral introductions rather than cryptic circulation of the previous genetic clusters in Buenos Aires during 2020. CONCLUSIONS: Following the reopening of borders, the reemergence of RSV in Argentina brought new viral introductions from other countries. Therefore, it is important to continue a deep global molecular surveillance to characterise RSV strains in post-pandemic circulation with an impact in future vaccine implementation.


Subject(s)
COVID-19 , Respiratory Syncytial Virus Infections , Respiratory Syncytial Virus, Human , Argentina/epidemiology , COVID-19/epidemiology , Child , Genotype , Humans , Infant , Pandemics , Phylogeny , Respiratory Syncytial Virus, Human/genetics , SARS-CoV-2/genetics
3.
medrxiv; 2021.
Preprint in English | medRxiv | ID: ppzbmed-10.1101.2021.08.22.21262186

ABSTRACT

Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we observed a similar process after Sputnik V vaccination. We examined the longitudinal antibody responses and viral neutralizing capacity to variants of concern (VOCs: Alpha, Beta, Gamma, and Delta) and a broadly spread variant of interest (VOI: Lambda) in volunteers up to 6 months after receiving the Sputnik V vaccine in Argentina. A collection of 1,800 serum samples obtained between January and August 2021 was used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing potency to the first-wave linages of SARS-CoV-2 and VOC increases within four months of vaccination, suggesting that antibody maturation occurs. This increase was more evident for the Beta and Gamma variants, which showed the highest propensity for neutralization escape. Our observations suggest that protection increases over the six months following vaccination as a consequence of antibody maturation, resulting in improved potency of antibodies to viral escape mutations.


Subject(s)
COVID-19 , Severe Acute Respiratory Syndrome
4.
Carolina Torres; Laura Mojsiejczuk; Dolores Acuna; Sofia Alexay; Ariel Amadio; Paula Aulicino; Humberto Debat; Franco Fernandez; Stephanie Goya; Guido Konig; Mercedes Nabaes Jodar; Luis Pianciola; Sofia Bengoa; Marco Cacciahue; Cecilia Camussone; Maria Jose Dus Santos; Maria Florencia Eberhardt; Ailen Fernandez; Maria Ines Gismondi; Matias Irazoqui; Silvina Lusso; Nathalie Marquez; Marianne Munoz; Monica Natale; Belen Pisano; Andrea Puebla; Viviana Re; Ezequiel Sosa; Jonathan Zaiat; Sebastian Zunino; Dario Do porto; Maria Elina Acevedo; Cristina Alvarez Lopez; Maria Laura Alvarez; Patricia Angeleri; Andres Angelletti; Manuel Arca; Gabriela Barbas; Ana Bertone; Agustina Bonnet; Ignacio Bourlot; Alejandro Castello; Gonzalo Castro; Carolina Ceriani; Carlos Cimino; Julian Cipelli; Maria Colmeiro; Andres Cordero; Carolina Cristina; Sofia Di Bella; Regina Ercole; Yesica Espasandin; Carlos Espul; Andrea Falaschi; Facundo Fernandez Moll; Andrea Gatelli; Sandra Goni; Maria E Jofre; Jose Jaramillo; Natalia Labarta; Maria A Lacaze; Rocio Larreche; Viviana Leiva; Gustavo Levin; Erica Luczak; Marcelo Mandile; Carla Massone; Melina Mazzeo; Carla Medina; Belen Monaco; Luciana Montoto; Viviana Mugna; Alejandra Musto; Guillermo Ojeda; Carolina Pintos; Marcia Pozzati; Marilina Rahhal; Claudia Rechimont; Federico Remes Lenicov; Gabriela Rompato; Vanesa Seery; Leticia Siri; Julieta Spina; Cintia Streitenberger; Ariel Suarez; Jorgelina Suarez; Paula Sujanski; Juan M Talia; Clara Theaux; Guillermo Thomas; Marina Ticeira; Estefania Tittarelli; Rosana Toro; Osvaldo Uez; Maria B Zaffanella; Cecilia Ziehm; Martin Zubieta; - PAIS Consortium; Alicia Mistchenko; Laura Valinotto; Mariana Viegas.
medrxiv; 2021.
Preprint in English | medRxiv | ID: ppzbmed-10.1101.2021.07.19.21260779

ABSTRACT

Molecular surveillance of SARS-CoV-2 variants was performed on a total of 2,406 samples from the capital city and nine provinces of Argentina, during 30 epidemiological weeks (EW) that covered the end of the first wave and the beginning of the ongoing second wave of the COVID-19 pandemic in the country (EW 44/2020 to EW 20/2021). The surveillance strategy was mainly based on Sanger sequencing of a Spike coding region that allows the simultaneous identification of signature mutations associated with worldwide circulating variants. In addition, whole SARS-CoV-2 genome sequences were obtained from 456 samples. The main variants found were Gamma, Lambda and Alpha, and to a lesser extent, Zeta and Epsilon. Whereas Gamma dominated in different regions of the country, both Gamma and Lambda prevailed in the most populated area, the metropolitan region of Buenos Aires (MABA), although showing a heterogeneous distribution along this region. This cost-effective surveillance protocol allowed for a rapid response in a limited access to resources scenario, added information on the expansion of the Lambda variant in South America and contributed to the implementation of public health measures to control the disease spread in Argentina.


Subject(s)
COVID-19
SELECTION OF CITATIONS
SEARCH DETAIL